These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9676300)

  • 1. Aldesleukin therapy in HIV-infected patients.
    Sundin DJ; Wolin MJ
    Am J Health Syst Pharm; 1998 Jul; 55(14):1520-3. PubMed ID: 9676300
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant Interleukin-2 (rIL-2), aldesleukin.
    Baigent G
    J Biotechnol; 2002 May; 95(3):277-80. PubMed ID: 12007868
    [No Abstract]   [Full Text] [Related]  

  • 3. Spotlight on interleukin-2 (IL-2, proleukin).
    Proj Inf Perspect; 2001 Mar; (32):13-5. PubMed ID: 11682774
    [No Abstract]   [Full Text] [Related]  

  • 4. Aldesleukin shows promise.
    AIDS Patient Care STDS; 1999 May; 13(5):307. PubMed ID: 10356813
    [No Abstract]   [Full Text] [Related]  

  • 5. IL-2 immunotherapy does not benefit patients taking antiretrovirals.
    AIDS Patient Care STDS; 2009 Mar; 23(3):221-2. PubMed ID: 19866543
    [No Abstract]   [Full Text] [Related]  

  • 6. Interleukin-2 in HIV infection.
    Minor JR
    Am J Health Syst Pharm; 1995 Jun; 52(12):1345-6. PubMed ID: 7656123
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin-2 (IL-2, Proleukin) and immune function.
    Proj Inf Perspect; 2003 Jan; (35):16. PubMed ID: 12647677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
    Kilby JM; Bucy RP; Mildvan D; Fischl M; Santana-Bagur J; Lennox J; Pilcher C; Zolopa A; Lawrence J; Pollard RB; Habib RE; Sahner D; Fox L; Aga E; Bosch RJ; Mitsuyasu R;
    J Infect Dis; 2006 Dec; 194(12):1672-6. PubMed ID: 17109338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2: trials and tribulations.
    Kuritzkes DR
    J Infect Dis; 2009 Jul; 200(2):164-5. PubMed ID: 19508158
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase III trial of IL-2.
    AIDS Patient Care STDS; 1999 Dec; 13(12):753-4. PubMed ID: 10743542
    [No Abstract]   [Full Text] [Related]  

  • 11. Report from the 16th Conference on Retroviruses and Opportunistic Infections. No clinical benefit from adding IL-2 to ART.
    Henry K
    J Watch AIDS Clin Care; 2009 Apr; 21(4):29-30. PubMed ID: 19544613
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of interleukin-2 (proleukin, aldesleukin) in oncological practice].
    Gershanovich ML
    Vopr Onkol; 2003; 49(6):776-82. PubMed ID: 14976930
    [No Abstract]   [Full Text] [Related]  

  • 13. Improved treatment results with interleukin-2.
    HIV Hotline; 1998 May; 8(2):13-4. PubMed ID: 11365363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
    Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U
    AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263
    [No Abstract]   [Full Text] [Related]  

  • 15. Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death.
    Hicks CB
    J Watch AIDS Clin Care; 2010 Jan; 22(1):4. PubMed ID: 20617576
    [No Abstract]   [Full Text] [Related]  

  • 16. Interleukin 2 treatment for HIV infection.
    Blankson J; Siliciano RF
    JAMA; 2000 Jul; 284(2):236-8. PubMed ID: 10889599
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of interleukin-2 therapy on the proliferation and differentiation of CD4/CD25 positive and CD4/CD25 negative cells in HIV+ patients.
    Caggiari L; Zanussi S; D'Andrea M; Bortolin MT; Crepaldi C; Caffau C; Paoli PD
    Eur Cytokine Netw; 2001; 12(3):430-6. PubMed ID: 11566623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2.
    Markowitz N; Bebchuk JD; Abrams DI;
    Clin Infect Dis; 2003 Oct; 37(8):e115-20. PubMed ID: 14523786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldesleukin. Interleukin-2 (IL-2), IL-2 (Chiron), Macrolin, Proleukin, recombinant IL-2 (Chiron), T cell growth factor.
    Drugs R D; 1999 Oct; 2(4):267-70. PubMed ID: 10659407
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV-infected immunologic non-responders: can we provide a helping hand?
    Morse CG; Kovacs JA
    Enferm Infecc Microbiol Clin; 2008 Jan; 26(1):1-3. PubMed ID: 18208758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.